thebiostories

🌏 Available in: English | 한국어 How Was Venetoclax Developed? The Australian Story Behind a Breakthrough Cancer Therapy Every breakthrough medicine begins with a question. For Venetoclax, that question was not simply: How can we kill cancer cells? The deeper question was: Why do some cancer cells refuse to die? Today, Venetoclax is recognized as one of the most important targeted therapies for blood cancers, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Unlike traditional chemotherapy, Venetoclax works by targeting a specific survival mechanism used by cancer cells. It blocks a protein called BCL-2 , allowing cancer cells to restart a natural process called apoptosis , or programmed cell death. However, the story of Venetoclax did not begin with a drug. It began decades earlier with a fundamental discovery made in a Melbourne research laboratory. The Melbourne Discovery That Changed Cancer Biology The story begins a...

🌏 Available in: English | 한국어 Decoding Drug Names: Why "-mab," "-nib," and "-clax" Aren't Random If you've spent any time reading about modern medicine, you've probably noticed that drug names seem to follow a pattern. Venetoclax (sold under the brand name Venclexta or Venclyxto, AbbVie and Roche). Pembrolizumab (sold under the brand name Keytruda, Merck). Imatinib (sold under the name of Gleevec, Novartis). Olaparib (sold under the brand name Lynparza, AstraZeneca and Merck). They sound engineered — and they are. These endings aren't marketing choices or accidents of pronunciation. They're part of a deliberate, internationally coordinated naming system that tells scientists, doctors, and pharmacists exactly what kind of drug they're looking at before they read a single word of the label. The system is overseen by naming bodies like the United States Adopted Names (USAN) Council and the International Nonproprietary Names (INN...